Search
SMART101
go.drugbank.com/drugs/DB18370InvestigationalSMART101 is an investigational cell therapy comprising human allogeneic CD34-CD7+ T cell progenitors that were cultured ex vivo.
RAPA-201
go.drugbank.com/drugs/DB18446InvestigationalRAPA-201 is an autologous rapamycin-resistant T-cell therapy.
Synonyms: Rapamycin-resistant autologous Th1/Tc1 T-cellsASP-2138
go.drugbank.com/drugs/DB18473InvestigationalASP-2138 is a bispecific antibody directed against CLDN18.2 and T cell receptor complex CD3
Heparan-N-sulfatase (human, recombinant)
go.drugbank.com/drugs/DB18483InvestigationalRecombinant human heparan-N-sulfatase (rhHNS) is under investigation for the treatment mucopolysaccharidosis type IIIA.
Synonyms: Recombinant human heparan-N-sulfatase, Heparan-N-sulfatase (human, recombinant)PA3-17
go.drugbank.com/drugs/DB18569InvestigationalPA3-17 is CD7-directed chimeric antigen receptor (CAR) T-cell therapy.
Synonyms: Chimeric Antigen Receptor T Cells targeting CD7SPL84-23-1
go.drugbank.com/drugs/DB18575ExperimentalSPL84-23-1 is a sodium salt of 19-bp single-stranded RNA uniformly modified 2'-O-(2-methoxyethyl) phosphorothioate Antisense Oligonucleotide (ASO) consisting of 19 nucleotide residues with the sequence
TRK-001
go.drugbank.com/drugs/DB18577InvestigationalTRK-001 is an autologous regulatory T-cell therapy. It is being investigated for the prevention of graft rejection following solid organ transplantation.
Synonyms: Natural Regulatory T Cells (T-Regs), Expanded with Interleukin-2, ExpAct Beads (CD3/CD28; Miltenyi), Rapamycin and Transforming Growth Factor-betaVCA-894A
go.drugbank.com/drugs/DB18609InvestigationalVCA-894A is a synthetic 2'-O-methoxyethyl phosphorothioate oligoribonucleotide sodium salt consisting of 19 nucleotide residues with the sequence 5'-MeCMeUGMeUGGAAGMeUGAGGGMeCMeCAG-3'
CTX130
go.drugbank.com/drugs/DB18627InvestigationalCTX130 is an allogeneic CRISPR/Cas9-mediated genetically modified CAR T cell therapy targeting CD70 antigen.
Synonyms: Allogeneic CRISPR/Cas9-mediated genetically modified CAR T cells targeting CD70 antigenALLO-605
go.drugbank.com/drugs/DB18641InvestigationalALLO-605 is an allogeneic turbo chimeric antigen receptor (Turbocar) T Cell therapy targeting B Cell maturation antigen (BCMA).